FREE PREVIEW
Weight-Loss Peptides
Read trial results, harms, formulation differences and treatment withdrawal in context.
AI-assisted editorial edition · Independent clinical review pending.
Before you read
Medical notice: This selected-source evidence-reading edition is educational material for a conversation with a qualified clinician. It does not diagnose a condition, recommend a medicine, supplement, injection or dose, or replace individualized care. Do not start, combine, stop or restart a treatment using this guide. Human editorial and independent clinical review are pending. Purchases and PDF downloads are not yet available.
What this edition can and cannot answer
Selected-source evidence-reading edition covering semaglutide STEP 1, tirzepatide SURMOUNT-1 and SURMOUNT-5, withdrawal evidence, dated pharmaceutical labeling and online product-quality findings. No complete comparative clinical synthesis, treatment selection, dosing or stack instructions.
- Selected-source editorial edition: five cited scholarly reports were reconciled in full; SURMOUNT-5 remains abstract/registry-limited. A registry or protocol is not a completed journal appraisal. Independent approvals remain pending.
- STEP 1 and SURMOUNT-1 are different placebo-controlled trials. Their averages do not supply a randomized comparison between medicines. [1] [2]
- Withdrawal studies have different designs and baselines; study averages do not predict one person’s outcome. [3] [4]
- Human editorial, independent clinical, legal, accessibility and reader-test approvals are pending. Purchases and PDF downloads are not yet available.
SECTION 01
Weight-Loss Peptides: Results, Tradeoffs and Stopping
Compare the claim with the tested product, population, outcome and follow-up. Use the findings table, then bring the worksheet and your questions to the clinician responsible for your care.
STEP 1 studied subcutaneous semaglutide against placebo; SURMOUNT-1 studied tirzepatide against placebo, and SURMOUNT-5 directly compared the two medicines under its own trial conditions. [1] [2] [5]
Selected-source checks: 27 October 2026. Five cited scholarly reports were reconciled in full; SURMOUNT-5 remains abstract/registry-limited. Independent review and broader clinical synthesis remain pending.
SECTION 02
What the selected studies found
Read each row within its own population, comparison and follow-up.
| Study and comparison | Finding in the studied population | Decisive limit |
|---|---|---|
| STEP 1: semaglutide vs placebo | At 68 weeks, mean body-weight change was -14.9% vs -2.4%; both groups received lifestyle intervention. [1] | Adults with overweight or obesity without diabetes; this was not a tirzepatide comparison. |
| SURMOUNT-1: tirzepatide vs placebo | At 72 weeks, mean weight reduction across three tirzepatide groups was 15.0%-20.9% vs 3.1% with placebo. [2] | Different trial from STEP 1; no comparison between medicines follows from these rows. |
| SURMOUNT-5: direct comparison | At 72 weeks, mean weight change was -20.2% with tirzepatide vs -13.7% with semaglutide under the trial regimens. [5] | Open-label, manufacturer-funded trial in adults with obesity without diabetes; average weight is one outcome. |
| STEP 1 extension: after withdrawal | The prior semaglutide group regained 11.6 percentage points during the following year; net change from original baseline was -5.6%. [3] | Subset follow-up; structured lifestyle intervention also stopped. |
| SURMOUNT-4: continue vs withdraw | Over 52 weeks after randomization, mean change was +14.0% after switch to placebo vs -5.5% with continued tirzepatide. [4] | Percentages use weight at randomization after initial treatment; people who stopped before randomization are not represented. |
Safety: labels contraindicate use with personal/family medullary thyroid carcinoma, MEN2 or specified hypersensitivity. They direct stopping and urgent help for persistent severe abdominal pain or serious allergic symptoms. This is not the complete safety list. [6] [7]
FOLLOW THE EVIDENCE
Sources and reading limits
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Full report checked; independent review pending
Main report Table 2/PDF p8/printed p996 and Results/PDF pp5-6; Methods/PDF pp2-4; Table 3/PDF p10; protocol/SAP selected objective and estimand sections.
Tirzepatide Once Weekly for the Treatment of Obesity
Full report checked; independent review pending
Main report Table 2/PDF p7/printed p211; participant flow/PDF p4; Table 4/PDF pp10-11; protocol/SAP objective/estimand sections.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Full report checked; independent review pending
Main report Results 3.1-3.2/PDF pp6-7/printed pp1558-1559; Methods 2.2-2.4; protocol Amendment6/PDF pp149-155.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Full report checked; independent review pending
Main report Methods/Statistical Analysis; Results/Table 2 (treatment-regimen estimand); Figure 1 and Table 3; registry NCT04660643 identifies distinct efficacy-estimand results; protocol/SAP selected sections.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Abstract/registry-limited finding; full journal appraisal pending; original paper linked below
PubMed abstract and NCT05822830 registry: primary weight-change results and participant flow; selected protocol/SAP sections. Full journal report remains unavailable.
WEGOVY U.S. Prescribing Information, revised June 2026
Current official snapshot checked 27 October; human clinical/legal approval pending
Prescribing Information §§4-8,§12 and Medication Guide; current snapshot 27 October 2026; revisedJune 2026(Wegovy) orAugust 2026(Zepbound).
ZEPBOUND U.S. Prescribing Information, revised August 2026
Current official snapshot checked 27 October; human clinical/legal approval pending
Prescribing Information §§4-8,§12 and Medication Guide; current snapshot 27 October 2026; revisedJune 2026(Wegovy) orAugust 2026(Zepbound).
Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases
Full report checked; independent review pending
Accepted full XML: Methods; Results and Online Vendor Characteristics table; Discussion; current PubMed PMID 39093567 metadata.
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
U.S. safety context; not efficacy evidence
Current FDA unapproved-GLP1 safety context, content 1 October 2026; checked 27 October 2026.
Edition and corrections
Web reading edition: 4 November 2026. Manuscript prepared: 2026-10-27. This web-format update does not represent a new literature search or completed clinical review.
Edition: weight-management-2026-10-27-source-checked-draft-1
Scientific interpretation, source-access limits and independent review are separate from publication of this reading view.
Report a correction →